Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the randomised part of the study is to investigate the efficacy and safety
of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug
naive or previously treated (4 weeks wash-out, 2 weeks placebo run-in) type 2 diabetic
patients with insufficient glycaemic control. For the open-label part of the study the
objective is to estimate the efficacy and safety of BI 1356 and metformin in type 2 diabetic
patients with very poor glycaemic control for 24 weeks